Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

UNDER EMBARGO UNTIL Tuesday, June 10, 2025, 3 a.m. EDT, CLEVELAND: A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

UNDATED (WKRC) - Weight-loss medications may not be as effective in "real-world" settings as they are in clinical trials, ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Real-world study shows injectable GLP-1 drugs for obesity have lower weight loss due to treatment discontinuation.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...